Medical/Pharmaceuticals
ExoCoBio's First Global Regenerative Aesthetic Exosome Summit
* World First Regenerative Aesthetic Exosome Summit (RAES 2022) * Participation of Global Exosome and Regenerative Aesthetic Authorities * Plan to Grow into a Global Platform for Exosome and Regenerative Aesthetic Industry in the Future SEOUL, South Korea, Aug. 16, 2022 /PRNewswire/ -- ExoCo...
2022-08-16 15:00
6287
Sirnaomics Develops Peptide Docking Vehicle (PDoV(TM)) Designed for an Enhanced GalNAc Delivery Platform for Novel siRNA Therapeutics
A proprietary GalNAc delivery system with enhanced Endosome Escape and Dual-Targeting GAITHERSBURG, Md. and SUZHOU, China, Aug. 16, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi ...
2022-08-16 14:48
3013
ICP DAS - BMP will attend MEDICAL MANUFACTURING ASIA 2022 in Singapore
TAIPEI, Aug. 16, 2022 /PRNewswire/ -- ICP DAS - BMP (Biomedical Polymers), a Taiwanese medical TPU (thermoplastic polyurethane) supplier, will exhibit at MEDICAL MANUFACTURINGASIA 2022, the 5th Manufacturing Processes for Medical Technology Exhibition and Conference, which provides excellent busi...
2022-08-16 10:15
2940
Antengene Announces First Patient Dosed of Small Molecule ATR ATG-018 for the Treatment of Patients with Advanced Solid Tumors and Hematologic Malignancies in Australia
* ATG-018, a global rights asset developed by Antengene's internal R&D team, is anorally-bioavailable, small molecule ataxia telangiectasia and Rad3-associated (ATR) kinase inhibitorthat targets the DNA damage response (DDR) pathways. * The Phase I study will evaluate the safety, pharmacology...
2022-08-16 08:30
2940
Gannex Announces First Subject Dosed in the U.S. Drug-Drug Interaction Study of FXR Agonist ASC42 for Treatment of Primary Biliary Cholangitis
-- Enrollment of the total 12 subjects is expected to be completed in August 2022 -- The DDI study on ASC42 in the U.S. is expected to be completed by the beginning of the fourth quarter 2022 -- This DDI study and ongoing Phase II clinical trial in PBC patients in China will provide more eviden...
2022-08-16 08:10
2621
Everest Medicines Enters into Agreement with Gilead Sciences for Trodelvy in Asia Territories
Everest to receive total considerations of up to $455 million with $280 million in upfront payments Broadens development and access to Trodelvy for patients in Greater China and certain Asia Pacific Markets Strengthens balance sheet and streamlines resources to advance robust pipeline of first-...
2022-08-16 07:15
3110
ROKIT Healthcare to Enable Innovation in Treatment of Diabetes Foot and Osteoarthritis Combining AI and 3D Bioprinting on Google Cloud
- Medical platform that converges Cloud, AI, and 3D bioprinting expected to dramatically improve treatment rate and medical access. SEOUL, South Korea, Aug. 12, 2022 /PRNewswire/ -- ROKIT Healthcare, a company specializing in bio-healthcare, today announced it will provide a hyper-personalized ...
2022-08-12 20:00
14792
Seegene reports H1 2022 financial results
* H1 revenue fell 11% YoY to KRW 579.9 billion, operating profit down 37% to KRW 212.7 billion * Decline due to drop in Q2 sales amid reduced PCR testing volume * Sales of non-COVID products and PCR instruments increased in H1; Company launches STARlet-AIOS to strengthen sales foundation *...
2022-08-12 19:00
14269
Menarini Group's Elacestrant Granted Priority Review by the U.S. FDA for Patients with ER+/HER2- Advanced or Metastatic Breast Cancer
* Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be availablefor patients suffering from 2L and 3L ER+/HER2- advanced or metastatic breast cancer * Submission supported by results from the pivotal Phase 3 EMERALD study of elacestrantshowing st...
2022-08-11 20:08
3434
Everest Medicines Announces Regulatory Update and Strategic Partnership for Xerava™ in Taiwan
Taiwan FDA accepts New Drug Application for Xerava for treatment of cIAI
Everest enters into strategic partnership with TTY Biopharm for the
commercialization of Xerava inTaiwan
SHANGHAI, Aug. 11, 2022 /PRNewswire/ -- Everest Medicines
2022-08-11 08:00
2842
Recbio announces Phase III Clinical Trial Progress Of Recombinant HPV 9-Valent Vaccine
TAIZHOU, China, Aug. 10, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the"Company", together with its subsidiaries, the "Group", Stock code: 02179.HK) is pleased to announce that, the Company has recently completed the subject enrollment and first dose vaccination in respect of immun...
2022-08-10 16:06
2743
Starpharma signs new DEP® agreement with MSD
MELBOURNE, Australia, Aug. 10, 2022 /PRNewswire/ -- Australian biotechnology company Starpharma today announced it has signed a new DEP® Research Agreement with MSD, the trade name of Merck Sharp & Dohme LLC,Rahway, NJ, USA. This new DEP® program will generate and evaluate additional DEP® Antibod...
2022-08-10 15:29
1828
MedAlliance SELUTION SLR Receives Second FDA IDE Approval
GENEVA, Aug. 10, 2022 /PRNewswire/ -- SELUTION SLR™, MedAlliance's novel sirolimus-eluting balloon, has received conditional FDA Investigational Device Exemption (IDE) approval to initiate its pivotal clinical trial for the treatment of occlusive disease of the superficial femoral artery (SFA). ...
2022-08-10 10:00
2848
Innovent Announces Phase 2 Clinical Study of Picankibart (IBI112) in Chinese Patients with Moderate-to-severe Plaque Psoriasis Met Primary Endpoint
SAN FRANCISCO and SUZHOU, China, Aug. 10, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and...
2022-08-10 08:00
3216
ONESIGHT ESSILORLUXOTTICA FOUNDATION ANNOUNCES PUBLICATION OF NEW ARTICLE
Article addresses role of advocacy in advancing healthy vision to meet Sustainable Development Goals DALLAS, Aug. 10, 2022 /PRNewswire/ -- OneSight EssilorLuxottica Foundation (Foundation) is pleased to announce the publication of a peer-reviewed article, The Power of Advocacy: Advancing Vision f...
2022-08-10 02:00
2402
Frost & Sullivan Institute Recognizes Samsung Biologics with the 2022 Global Enlightened Growth Leadership Award for its Commitment to Sustainable Growth
Samsung Biologics' mission to create a better world through high-quality biopharmaceuticals is underscored by a series of global initiatives to deliver progress related to climate change SAN ANTONIO, Aug. 9, 2022 /PRNewswire/ -- Frost & Sullivan Institute is proud to present Samsung Biologics wi...
2022-08-09 21:17
2555
Merck Becomes One of the First CDMOs to Provide Full Viral Vector Offering with Launch of VirusExpress® 293 Adeno-Associated Virus Production Platform
* Reduces process development time by an estimated 40 percent * Enables biopharmaceutical companies to increase the speed to clinical manufacturing * Adds to company's best-in-class VirusExpress® Lentiviral Production Platform DARMSTADT,Germany, Aug. 9, 2022 /PRNewswire/ -- Merck, a leading s...
2022-08-09 20:00
2912
Novaliq submits New Drug Application seeking approval for first-of-a-kind Dry Eye Disease Treatment CyclASol®
HEIDELBERG, Germany, and CAMBRIDGE, MA, Aug. 9, 2022 /PRNewswire/ -- Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, today announced the submission of a New Drug Application (NDA) to the U.S. Food and...
2022-08-09 19:00
2042
First Patient Dosed in Phase II Study of KN046 Combined with Axitinib for the First Line Treatment of Advanced Non-Small Cell Lung Cancer
SUZHOU, China, Aug. 9, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced the first patient has been dosed in the phase II clinical study (KN046-209) of PD-L1/CTLA-4 bispecific antibody KN046 plus Axitinib for the first line treatment of advanced Non-Small Cell Lung Cancer (NS...
2022-08-09 11:18
3133
Sciwind Biosciences Reports Positive Interim Results from Phase 1c/2a Clinical Trial of XW003 (Ecnoglutide) in Overweight and Obese Adult Volunteers in China
* Mean body weight loss of 9.6% and 9.0% in participants receiving 1.8 mg and 2.4 mg XW003 for 14 weeks, respectively * Up to 72.4% of participants achieved weight loss of at least 5% at week 14 * XW003 was safe and well tolerated with gastrointestinal side effects as the most commonly repor...
2022-08-09 08:00
2355
Week's Top Stories
Most Reposted
Alpha Trading Cup 2024 Award Night: Top Trader Achieves Remarkable 315% Profit, as Over 1,149 Competitors Vie for USD 44,000 Prize Pool
[Picked up by 313 media titles]
2024-10-25 18:29
International Golo Mori Jazz 2024: Experience the Harmony of Eastern Indonesia's Exotic Beauty and Romantic Jazz Music
[Picked up by 300 media titles]
2024-10-25 22:48
2024 Malaysia E-commerce Product Selection Expo Reaches Major Milestone Attracting Leading Brands and Businesses From China
[Picked up by 300 media titles]
2024-10-25 07:00
RuggON Showcases Latest Mining Technology at IMARC 2024
[Picked up by 294 media titles]
2024-10-28 14:32
TotalEnergies ENEOS Completes a 1.8 MWp Floating Solar Photovoltaic System Project, a Second Collaboration with S. Kijchai Enterprise in Thailand
[Picked up by 288 media titles]
2024-10-29 11:24
Most Read
Alpha Trading Cup 2024 Award Night: Top Trader Achieves Remarkable 315% Profit, as Over 1,149 Competitors Vie for USD 44,000 Prize Pool
2024-10-25 18:29
8598
International Golo Mori Jazz 2024: Experience the Harmony of Eastern Indonesia's Exotic Beauty and Romantic Jazz Music
2024-10-25 22:48
7452
Infobip and Singtel Partner to Advance Customer Engagement for Singapore Businesses with Rich Communication Services
2024-10-25 12:30
7032
Global development relies on cooperation
2024-10-25 12:38
5995
Peak Energy CEO Gavin Adda Speaks at Asia Clean Energy Summit 2024
2024-10-25 18:30
5704
